Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review
International Journal of Molecular Sciences · 03.02.2023 · 24 (3) · 2969
DOI: 10.3390/ijms24032969 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.02.2023. Verfasst von Nadine S van den Ende und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, 3015 GD Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 214-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NWO.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Around 40–50% of all triple-negative breast cancer (TNBC) patients achieve a pathological complete response (pCR) after treatment with neoadjuvant chemotherapy (NAC). The identification of biomarkers predicting the response to NAC could be helpful for personalized treatment. This systematic review provides an overview of putative biomarkers at baseline that are predictive for a pCR following NAC. Embase, Medline and Web of Science were searched for articles published between January 2010 and August 2022. The articles had to meet the following criteria: patients with primary invasive TNBC without distant metastases and patients must have received NAC. In total, 2045 articles were screened by two reviewers resulting in the inclusion of 92 articles. Overall, the most frequently reported biomarkers associated with a pCR were a high expression of Ki-67, an expression of PD-L1 and the abundance of tumor-infiltrating lymphocytes, particularly CD8+ T cells, and corresponding immune gene signatures. In addition, our review reveals proteomic, genomic and transcriptomic markers that relate to cancer cells, the tumor microenvironment and the peripheral blood, which also affect chemo-sensitivity. We conclude that a prediction model based on a combination of tumor and immune markers is likely to better stratify TNBC patients with respect to NAC response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, 3015 GD Rotterdam, The Netherlands.
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, 3015 GD Rotterdam, The Netherlands.
- Department of Medical Oncology, Tumor Biology & Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
ORCID-Profile: Nadine S van den Ende, Marleen Kok, Reno Debets
Förderung
- NWO
Zitieren
APA
van den Ende, N. S., Nguyen, A. H., Jager, A., Kok, M., Debets, R., & van Deurzen, C. H. M. (2023). Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. International Journal of Molecular Sciences, 24(3), 2969. https://doi.org/10.3390/ijms24032969
Vancouver
van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CHM. Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. International Journal of Molecular Sciences. 2023;24(3):2969. doi:10.3390/ijms24032969
BibTeX
@article{vandenEnde2023,
author = {van den Ende, Nadine S and Nguyen, Anh H and Jager, Agnes and Kok, Marleen and Debets, Reno and van Deurzen, Carolien H M},
title = {Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {3},
pages = {2969},
doi = {10.3390/ijms24032969}
}
EUVIMED